CAJ | 학술논문

目的比较派特灵与膦甲酸钠治疗宫颈高危型人乳头瘤病毒(HPV)感染的疗效.方法选择高危型HPV持续感染且宫颈薄层液基细胞学技术(TCT)正常或组织病理学诊断≤宫颈上皮内瘤变(CIN)Ⅰ级,完成随访的125例患者分成派特灵组(47例),按照派特灵用药说明宫颈局部上药6个疗程;膦甲酸钠组(40例),3g/d静脉滴注15 d;对照组(38例),仅随访观察.所有研究对象治疗结束后第6、12个月进行HPV复查.结果三组患者中HPV16单一感染33例(26.4％),多亚型复合感染23例(18.4％).经12个月随访,HPV转阴情况:派特灵组37例(78.7％),膦甲酸钠组23例(57.5％),对照组22例(57.9％).HPV转阴率显示,派特灵组高于对照组和膦甲酸钠组,差异有统计学意义(x2=4.293、4.548,P＜0.05),膦甲酸钠组与对照组比较差异无统计学意义(x2=0.001,P＞0.05).治疗过程中,患者无明显不良反应.结论派特灵对高危型HPV感染有一定的逆转作用,且安全无明显副作用,而膦甲酸钠无明显疗效.
목적 비교파특령여련갑산납치료궁경고위형인유두류병독(HPV)감염적료효.방법 선택고위형HPV지속감염차궁경박층액기세포학기술(TCT)정상혹조직병이학진단≤궁경상피내류변(CIN)Ⅰ급,완성수방적125례환자분성파특령조(47례),안조파특령용약설명궁경국부상약6개료정;련갑산납조(40례),3g/d정맥적주15 d;대조조(38례),부수방관찰.소유연구대상치료결속후제6、12개월진행HPV복사.결과 삼조환자중HPV16단일감염33례(26.4％),다아형복합감염23례(18.4％).경12개월수방,HPV전음정황:파특령조37례(78.7％),련갑산납조23례(57.5％),대조조22례(57.9％).HPV전음솔현시,파특령조고우대조조화련갑산납조,차이유통계학의의(x2=4.293、4.548,P＜0.05),련갑산납조여대조조비교차이무통계학의의(x2=0.001,P＞0.05).치료과정중,환자무명현불량반응.결론 파특령대고위형HPV감염유일정적역전작용,차안전무명현부작용,이련갑산납무명현료효.
Objective To compare the therapeutic efficacy of paiteling and foscamet sodium on persistent infection of high-risk human papillomavirus (HPV).Methods One hundred and twenty-five cases of high-risk HPV persistent infection with normal thinprep cytologic test (TCT) report or whose pathology diagnosis ≤CIN Ⅰ were selected.They were divided into three groups:paiteling group (n=47),foscarnet sodium group (n=40),and control group (n =38).Paiteling was given according to the instructions for 6 courses; foscarnet sodium was given intravenously 3 g/d for 15 days; and control group was under observation without any treatment.All patients were followed up for 12 months and HPV test was performed at 6 months and 12 months,respectively.Results Patients with single HPV16 infection accounted for 26.4％ (33 cases) and patients with multiple infections accounted for 18.4％ (23 cases).After a 12-month follow-up,the HPV negative rate was 78.7％(37 cases) in paiteling group,57.5％(23 cases) in foscarnet sodium group,and 57.9％(22 cases) in control group,with a statistically significant difference between paiteling group and other two groups (x2=4.293,4.548,P＜0.05),but no statistically significant difference between foscarnet sodium group and control group (x2=0.001,P＞0.05).No adverse event occurred in all three groups.Conclusions Paiteling is effective and safe on treating persistent infection of high-risk HPV,while foscarnet sodium has hardly any efficacy against the disease.